Category Archives: Inside BIO Industry Analysis

ARPA-E Innovation Summit Comes to Washington, DC.

arpa-e-logo

The U.S. Department of Energy’s ARPA-E Innovation Summit is scheduled for February 24-26, 2014 in Washington, DC. The Advanced Research Projects Agency-Energy (ARPA-E) funds transformational projects that create entirely new ways to generate, store, and use energy. Since September 2013, ARPA-E has announced almost $125 million in funding for new projects aimed at finding innovative ways to lower the cost and improve the efficiency of energy technologies. “We’re investing in the best people, the best Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

2013 Novel Drug Approvals

Therapeutic-Indications-with-Novel-Drug-Approvals-in-2013-115x76

The FDA approved 24 novel drugs last year by our count, in line with average approvals for the last ten years but down from the decade-high approvals seen in 2012. Our count is a bit lower than the FDA’s count of 27 new approvals, because we did not include imaging agents like Navidea’s Lymphoseek, or reformulations like J&J’s Simponi Aria. 2013 was the first year the breakthrough-designated therapies were approved, with three breakthrough therapies approved: Gilead’s Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

#BIOBuyside Twitter Chat: What Do Biotech Investors Expect in 2014?

Dave Thomas

Is 2014 a good time to invest in biotech? How many biotech IPOs will there be? Which sectors will perform the best? To find out what investors think about these questions and more, BIO is conducting its annual Buy-side Investor Perception Survey and releasing the results at the 16th Annual BIO CEO & Investor Conference in New York, Monday Feb. 10. But as the results are coming in, BIO is hosting the #BIOBuyside Twitter chat Read More >

Inside BIO Industry Analysis  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,

Fewer Small Public Biotechs Today

Fig2-size-2008-vs-2013-115x76

A lot can happen in six years. The number of active biotech companies currently trading on US exchanges is now only 300. At the start of 2008, there were almost 400 active companies.   The net decrease in the number of active companies since 2008 is 24%. Had it not been for all the IPO activity we have seen this year, the decrease would have been substantially more. In fact, only 55% of the original Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Biotech Stocks Hit Record Highs…Again

BIOtech-stocks

Biotech stocks hit an all-time high this week, driven by strong performance among large cap sector leaders with strong product portfolios. A common benchmark for the sector, the NASDAQ Biotechnology Index (NBI) has outperformed the S&P 500 by a factor of over 2X. The NBI is up 61% year to date, compared with 26% for the S&P 500. We’ll be discussing this strong performance in New York this February at the BIO CEO & Investor Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,